Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 19

CN70 - Patients with glioblastoma and seizures: Insights into care

Date

10 Sep 2022

Session

Poster session 19

Topics

Supportive Care and Symptom Management;  Patient Education and Advocacy;  Communication Skills;  Multi-Disciplinary and Multi-Professional Cancer Care

Tumour Site

Central Nervous System Malignancies

Presenters

Deborah O'Doherty

Citation

Annals of Oncology (2022) 33 (suppl_7): S827-S836. 10.1016/annonc/annonc1046

Authors

D. O'Doherty, O.M. Fitzpatrick, T. Doyle, D.J. McMahon, L. Judge, R.A. Mclaughlin, C. Matassa, M. Conroy, N. Cooley, F.E. Barrett, O.S. Breathnach, S. Hamilton

Author affiliations

  • Medical Oncology, Beaumont RCSI Cancer Centre, D09 FT51 - Dublin/IE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN70

Background

Seizures are reported as the initial presentation in up to 45% of patients with Glioblastoma multiforme (GBM). Up to 80% of patients however can develop seizures during the whole course of their disease. Patient insight into seizures is therefore an important aspect of their care. We assessed patients' and carers' knowledge of the common forms of seizure activity to identify potential gaps in their understanding of GBM-related seizures and their associated urgent management.

Methods

Patients with GBM and their carers attending the oral chemotherapy clinic over a 2 week period were offered to participate in a questionnaire-based assessment. The questionnaire was designed to look at the symptoms & signs of seizures, whether they were currently on anti-seizure medication, the role of buccal midazolam, and whether they were content with the information they had received.

Results

Of the 42 candidates approached, 38 participated with the questionnaire. 55% were patients, the reminder were carers (n=17). From a list of 12 signs of seizures 57% of patients and 35% of carers were able to identify 5 or more signs. Anti-seizure medications were being taken by 76% of patients. 42% had a prior seizure, with 33% having a history of at least 2 seizures. Of the patients who had experienced a seizure only 33% had heard of buccal midazolam, and only 18% of their carers. Of those confident about seizure recognition, only 42% of patients were content with the information they had received about seizures.

Conclusions

Though seizures are a real reality for many of our patients with GBM, the level of knowledge within patients and their carers about seizures and their managment was moderate. The low awareness within the cohort assessed regarding the benefits of buccal midazolam and of how to administer it was concerning. This pilot assessment demonstrates a need to reconsider the approach to the holistic care of our patients with GBM, beyond the usual limited focus on systemic chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Beaumont Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.